anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Autologous hematopoietic stem cell transplantation (ASCT) has emerged as a cornerstone in multiple myeloma (MM) management, offering the prospect of prolonged disease control. However, the induction chemotherapy drugs required prior to ASCT carry cardiovascular toxicity (CVT), potentially leading to a range of cardiovascular complications.
METHODS AND RESULTS: This retrospective observational study, conducted at Guangdong Provincial People's Hospital from January 2020 to December 2023, analyzed 47 of the initial 173 patients who met the criteria. The cohort, comprising 22 males (46.81%) and 25 females (53.19%), had a mean age of 55.68 ± 11.38 years. They underwent various induction chemotherapy regimens, receiving a median of 5 (4-6) cycles of the course over an average duration of 7.10 ± 2.46 months. Before ASCT treatment following induction chemotherapy, echocardiographic findings indicated reductions in left ventricular end-systolic dimension, right atrial diameter, E-wave velocity, E/e' ratio, and the E/A ratio. The latter altered from a pretreatment value greater than 1 to posttreatment less than 1, marking diastolic dysfunction emergence or aggravation in 51.06% of patients. The electrocardiographic data indicate a reduced heart rate and prolonged P-wave duration and P-R duration, with an increase in arrhythmia incidence to 19.15% following induction chemotherapy.
CONCLUSION: Induction chemotherapy, administered prior to ASCT in patients with MM, can lead to the emergence or aggravation of cardiac diastolic dysfunction and increase the incidence of arrhythmic events. Therefore, it is crucial to emphasize the importance of balancing the benefits and risks of induction chemotherapy to maximize its efficacy while minimizing CVT.
PURPOSE:To obtain a specific medicine for athlete's foot, by drying and crushing both or either one of SUGI (Japan Cedar) leaves and pine leaves to give a powdery or granular material, dipping the resultant powdery or granular material in acetic acid solution to swell the material. CONSTITUTION:SUGI leaves or pine leaves are collected dried thoroughly in the sun or in a dryer, and the dried leaves are crushed into a powdery or granular material in a crusher, etc. The resultant powdery or granular material is then dipped in an acetic acid solution, preferably an aqueous solution of about 3- 8wt% concentration and swelled to give the aimed agent. The mixing weight ratio between the aqueous solution of the acetic acid and the SUGI or pine leaves is about 6:4, and the powdery or granular material is dipped in the aqueous solution and allowed to stand for 2-3 days for swelling. The above-mentioned agent is applied uniformly to the affected part, and covered with a bandage,. etc. to permeate the active constituent into the affected part for about a half day. The resultant dried coated surface is removed to cure completely the itching of the skin and expel the trichophytes. The resuscitation of the skin in the state close to the natural cure is carried out without disavantages of damaging the skin by excessive irritation.
Patients receive pelareorep IV over 60 minutes on days 1, 2, 15, and 16. Patients also receive INCMGA00012 IV over 60 minutes on day 3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Endometrial polyps (EPs) are benign overgrowths of the endometrial tissue lining the uterus, often causing abnormal bleeding or infertility. This study analyzed gene expression differences between EPs and adjacent endometrial tissue to elucidate intrinsic abnormalities promoting pathological overgrowth. RNA sequencing of 12 pairs of EPs and the surrounding endometrial tissue from infertile women revealed 322 differentially expressed genes. Protein-protein interaction network analysis revealed significant alterations in specific signaling pathways, notably Wnt signaling and vascular smooth muscle regulation, suggesting these pathways play critical roles in the pathophysiology of EPs. Wnt-related genes DKK1 and DKKL1 were upregulated, while GPC3, GREM1, RSPO3, SFRP5, and WNT10B were downregulated. Relevant genes for vascular smooth muscle contraction were nearly all downregulated in EPs, including ACTA2, ACTG2, KCNMB1, KCNMB2, MYL9, PPP1R12B, and TAGLN. Overall, the results indicate fundamental gene expression changes promote EP formation through unrestrained growth signaling and vascular defects. The intrinsic signaling abnormalities likely contribute to clinical symptoms of abnormal uterine bleeding and infertility common in EP patients. This analysis provides molecular insights into abnormal endometrial overgrowth to guide improved diagnostic and therapeutic approaches for this troublesome women's health condition. Confirmation of expanded cohorts and further investigations into implicated regulatory relationships are warranted.
Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
PROBLEM TO BE SOLVED: To prepare the subject concentrate capable of containing an aromatic dialdehyde in a higher concentration while maintaining the physical stability of a pH buffer system and useful for the disinfection and pasteurization of medical instruments by including an aromatic dialdehyde with a concentration higher than a specific value, a solvent miscible with water and a buffering salt. SOLUTION: This concentrate contains (A) an aromatic dialdehyde (e.g. orthophthalaldehyde) in >5 wt./wt.% content, (B) a solvent miscible with water (e.g. ethanol) and (C) a buffering salt (e.g. monosodium dihydrogenphosphate/ disodium hydrogenphosphate). The concentrate is prepared pref. by mixing the ingredient A with the ingredient B, followed by adding the ingredient C to the mixture. The concentrate is used pref. as a kit produced by being composed of the first solution containing the ingredients A and B, and the second solution containing at least the ingredient C, and the two solutions can be separately held e.g. in a fractural chamber bottle.
Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
PURPOSE: A monoclonal antibody which is provided to quickly and accurately diagnose, prevent, and treat Vibrio vulnificus infection. CONSTITUTION: A monoclonal antibody binds to Vibrio vulnificus RtxA1 antigen and thermal-treated Vibrio vulnificus RtxA antibody. The monoclonal antibody binds to 3491-3980th amino acids of RtxA 1 antigen. A composition for detecting Vibrio vulnificus contains the monoclonal antibody. A it for diagnosing Vibrio vulnificus comprises the monoclonal antibody. A method for detecting Vibrio vulnificus comprises a step of contacting the monoclonal antibody with a biological sample and forming an antigen-antibody complex.
The present invention relates to a lyophilized preparation of puerarin which is composed of lipidosome of cardiovascular drug puerarin and pharmaceutically acceptable carrier. The lipidosome of cardiovascular drug puerarin is composed of puerarin, lipidosome component, surfactant and freeze-drying supporting agent, wherein the weight ratio of puerarin, lipidosome component, surfactant and freeze-drying supporting agent is 1:50-40:0.1-1.5:0.1-1. The lipidosome component is dimyristica lecithin and cholesterol. The weight ratio between the dimyristica lecithin and cholesterol is 20-2:1. The surfactant is polysorbate-80. The freeze-drying supporting agent selects mannitol. The lyophilized preparation of puerarin of the invention has the advantages of high enveloping rate, good stability, excellent solubility, and evident reduced hemolytic adverse reaction of puerarin.
Since March 2020, South Korea has implemented social distancing measures to reduce the spread of the coronavirus disease (COVID-19). These policies resulted in significant changes in the lifestyle of Korean adults, including spending more time indoors and experiencing increased sedentary time during the pandemic. This study aimed to investigate the combined influence of sedentary lifestyle and the COVID-19 pandemic on obesity rates among adults residing in South Korea. Data were obtained from the 2018-2020 Korea National Health and Nutrition Examination Survey (KNHANES). Multiple logistic regression was used to analyze the synergistic effects of a sedentary lifestyle and COVID-19 on obesity. The prevalence of sedentary lifestyles among the participants increased from 30.4% pre-COVID-19 to 36.6% during the pandemic. Furthermore, the obesity rates were raised independently by COVID-19 (OR: 1.16, 95% CI 1.04-1.30) and by a sedentary lifestyle (OR = 1.17, 95% CI 1.04-1.31). A synergistic effect of a sedentary lifestyle and COVID-19 on obesity was identified (OR: 1.57, 95% CI 1.30-1.85). COVID-19 and a sedentary lifestyle significantly increased the risk of obesity in South Korean adults. Moreover, the combined synergistic effects of these risk factors were too substantial to be disregarded by merely summing their individual effects on obesity.
This is a small study to assess the usability of video conferencing. A total of 10 patients will be enrolled, 5 of which will be Spanish speakers. All patients will test the video conferencing.
Sodium Phosphates Injection, USP, 3 mM P/mL (millimoles/mL), is a sterile, nonpyrogenic, concentrated solution containing a mixture of monobasic sodium phosphate and dibasic sodium phosphate in water for injection.

The solution is administered after dilution by the intravenous route as an electrolyte replenisher. It must not be administered undiluted.

Each mL contains 276 mg of monobasic sodium phosphate, monohydrate and 142 mg of dibasic sodium phosphate, anhydrous (equivalent to 268 mg of dibasic sodium phosphate, heptahydrate).

One mM of phosphorus weighs 31 mg, and the product provides 93 mg (approximately 3 mM) of phosphorus/mL plus 92 mg (4 mEq) of sodium/mL. Note: 1 mM P = 1 mM PO4. It contains no bacteriostat, antimicrobial agent or added buffer. The pH is 5.5 (5.0 to 6.0). The osmolar concentration is 7 mOsmol/mL (calc).

The solution is intended as an alternative to potassium phosphate to provide phosphorus for addition to large volume infusion fluids for intravenous use.

It is provided as a 5 mL, 15 mL and 50 mL partial fill single-dose vial; when lesser amounts are required, the unused portion should be discarded with the entire unit.

Monobasic Sodium Phosphate, USP (monohydrate) is chemically designated NaH2PO4• H2O, white, odorless crystals or granules freely soluble in water.

Dibasic Sodium Phosphate, USP (anhydrous) is chemically designated Na2HPO4, colorless or white granular salt freely soluble in water.

The semi-rigid container is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.
PURPOSE:An immunological regulator, containing a physiological active substance beta-alanine or a salt thereof as an active constituent, having immunological regulating action even on restoration of lesion tissues which is not found in the conventional immunological regulators and useful for immunological abnormality such as serum disease or rheumatism. CONSTITUTION:An immunological regulator containing beta-alanine expressed by the formula H2NCH2CH2COOH or a salt thereof as an active constituent. The beta-alanine is a physiologically active substance present in animal or plant tissues, and it has lately been found that the beta-alanine has improved immunological regulating action and is useful as an immunological regulator. The beta-alanine has the immunological regulating action even on the restoration of lesion tissues and is used nonspecifically for diseases of immunological abnormality, e.g. lupus erythematosus, mixed type cryoglobulinemia, collagenosis or Behcet's disease. The above-mentioned regulator may be orally or parenterally adminiatered, has high safety and can be used without fear for side effects.
We report the rare entity of ulcerative colitis-related severe enteritis (UCRSE) following colectomy in a child. This entity has been described primarily in adults and is characterised by diffuse enteritis with histology identical to ulcerative colitis (UC). The mainstay treatment is steroids and in recent years anti-tumour necrosis factor agents.A boy in early adolescence required urgent colectomy for medically refractory severe acute colitis. Colectomy specimen histology confirmed UC. Postoperatively, he developed fevers, severe abdominal pain and excessive stoma output (5 L/day). Endoscopy revealed severe extensive enteritis, histologically resembling UC. Infliximab (IFX) was commenced with significant improvement. He remains asymptomatic 28 months post-colectomy on maintenance IFX monotherapy. To our knowledge, this is the youngest patient with this complication.This case illustrates the need to consider UCRSE in a child with otherwise unexplained fever, severe abdominal pain and high stoma output post colectomy. IFX monotherapy is a successful treatment option.
Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method.  The present invention also includes pharmaceutical compositions. In more detail, the present invention provides molecular probes and methods for producing molecular probes. The present invention provides also provides systems and methods for new drug discovery. An embodiment of the present invention utilizes sets of probes of the present invention and a new approach to computational chemistry in a drug discovery method having increased focus in comparison to heretofore utilized combinatorial chemistry. The present invention also provides computer software and hardware tools useful in drug discovery systems. In an embodiment of a drug discovery method of the present invention in silico methods and in biologico screening methods are both utilized to maximize the probability of success while minimizing the time and number of wet laboratory steps necessary to achieve the success.
Stratum 1: This is a phase 2 single-arm open-label study that will define event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 131I-omburtamab in patients with recurrent medulloblastoma. Patients with recurrent medulloblastoma will undergo surgery if feasible prior to study entry, followed by Induction Chemotherapy with irinotecan, temozolomide, and bevacizumab on study as per the Children's Oncology Group (COG) trial ACNS0821. Following 2 or 4 courses of chemotherapy and if radiographic disease status is stable or improved, patients may continue to Radioimmunotherapy to receive 2 therapeutic doses (50 mCi each) of cRIT 131I-omburtamab. Following Radioimmunotherapy, patients may resume to Maintenance Chemotherapy with irinotecan, temozolomide, and bevacizumab for up to 12 total courses of chemotherapy or until disease progression, whichever occurs sooner. The primary comparison for this study will be the medulloblastoma cohort treated on ACNS0821 on the irinotecan + temozolomide + bevacizumab arm (N=52).

Stratum 2: This is a feasibility cohort. The primary objective is to assess feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma and to assess dosimetry. Patients must have progressed after initial surgery, radiation therapy, or other therapies. Patients will undergo surgery (if feasible) prior to study entry with the goal of achieving stable or better disease. Tumors (archived or new) will be tested for B7H3 prior to enrollment. If positive, patients will enroll on Stratum 2 and receive one dosimetry dose (2 mCi) of cRIT 131I-omburtamab with nuclear medicine scintigraphy (typically using 3 whole-body planar gamma camera imaging and at least 1 head SPECT scan or SPECT/CT) using SPECT during the Dosimetry Course (14 days in length). Following the Dosimetry Course and within 2 weeks of the dosimetry dose, patients may continue to Radioimmunotherapy to receive 2 therapeutic doses (50 mCi each) of cRIT 131I-omburtamab.
Objective: To evaluate the efficacy and safety of eculizumab in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China. Methods: Data from PNH patients who received at least 3 months of full-dose eculizumab and were followed for at least 3 months between December 2022 and July 2023 were retrospectively collected. We evaluated changes in clinical and laboratory parameters after 1, 2, 3, and 6 months of eculizumab treatment. The rates of breakthrough hemolysis (BTH), extravascular hemolysis (EVH), and the occurrence of adverse reactions were also monitored. Results: The study included nine patients, six males and three females, with a median age of 54 (28-69) years. 5 of the patients had classic PNH, while 4 had PNH/AA. The number of episodes of hemoglobinuria was 5 (1-25) per month before eculizumab. 4 patients required blood transfusion, 5 had thrombosis and one had renal impairment before eculizumab. The median time to eculizumab was 6 (3-7) months and the followup period was 3 (3-6) months after treatment. The number of episodes of hemoglobinuria following eculizumab was 0 (0-1). During the followup period, no additional thrombotic events occurred. LDH at any time after eculizumab was lower than at baseline, and some patients' HGB increased. All transfused patients became transfusion-independent after receiving eculizumab. The FACIT-Fatigue score improved by an average of 17.3 points following treatment. 2 patients developed BTH and improved with symptomatic treatment. There were three adverse events that caused mild symptoms. There are no serious adverse events or deaths. Conclusion: Eculizumab can effectively control the hemolytic-related symptoms of PNH in China, reducing the need for blood transfusions to some extent, while also demonstrating a higher safety profile.
The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: wherein α, β, and γ are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein K, p, and τ are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein χ, φ, γ, and ηare each integers whose values are independently selected. Alternatively, the linker structure may have the following structure: wherein λ and μ are each integers whose values are independently selected.
FIELD: medicine, oncology, pharmacy. SUBSTANCE: mixture medicinal form comprises 5-fluorouracil as conjugate with deoxyribonucleic acid sodium salt an aqueous solution taken as biologically active substance. The weight ratio of 5-fluorouracil to deoxyribonucleic acid sodium salt is from 3.3 to 25. For preparing the mixture medicinal form 5-fluoro- -uracil is dissolved in water at temperature from +4 to +25 C in darkness, solution of 5-fluorouracil is homogenized with deoxyribonucleic acid sodium salt an aqueous solution as biologically active substance to obtain the conjugate. The novel mixture medicinal form shows selective effect on tumor tissue and exhibits low toxicity. Agent can be used in decompensated elderly patients in stage of generalization of malignant process and carrying severe accompanying pathology. EFFECT: improved properties and enhanced effectiveness of medicinal form. 2 cl, 1 tbl
Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.
Skeletal muscle is composed of bundles of muscle fibers with distinctive characteristics. Oxidative muscle fiber types contain higher mitochondrial content, relying primarily on oxidative phosphorylation for ATP generation. Notably, as a result of obesity, or following prolonged exposure to a high-fat diet, skeletal muscle undergoes a shift in fiber type toward a glycolytic type. Mitochondria are highly dynamic organelles, constantly undergoing mitochondrial biogenesis and dynamic processes. Our study aims to explore the impact of obesity on skeletal muscle mitochondrial biogenesis and dynamics and also ascertain whether the skeletal muscle fiber type shift occurs from the aberrant mitochondrial machinery. Furthermore, we investigated the impact of exercise in preserving the oxidative muscle fiber types despite obesity. Mice were subjected to a normal standard chow and water or high-fat diet with sugar water (HFS) with or without exercise training. After 12 weeks of treatment, the HFS diet resulted in a noteworthy reduction in the markers of mitochondrial content, which was recovered by exercise training. Furthermore, higher mitochondrial biogenesis markers were observed in the exercised group with a subsequent increase in the mitochondrial fission marker. In conclusion, these findings imply a beneficial impact of moderate-intensity exercise on the preservation of oxidative capacity in the muscle of obese mouse models.
PURPOSE: A composition containing Angelica Keiskei Koid. extract for preventing and treating obesity is provided to reduce body weight and body fat. CONSTITUTION: A food composition for preventing and treating obesity contains Angelica Keiskei Koid. extract as an active ingredient. The extract is a non-soluble fraction of Angelica Keiskei Koid. organic solvent extract. A method for preparing the extract comprises: a step of preparing organic solvent extract of Angelica Keiskei Koid.; a step of adding water to the extract; and a step of removing water soluble ingredients. The organic solvent is alcohol of 1-6 carbon atoms, acetone, ethyl acetate, n-hexane, diethyl ether, acetone, or benzene. A pharmaceutical composition for preventing and treating obesity contains the extract as an active ingredient. [Reference numerals] (AA) Epididymis fat; (BB) Epididymis fat weight(g); (CC) Angelica Keiskei Koid. juice; (DD) Angelica Keiskei Koid. meal extract powder
The extract of Korean red ginseng has been found efficacious in the prevention of respiratory infections in healthy adults. The investigators will be conducted a randomized, double-blind, placebo-controlled study at the onset of the influenza season. A total of 100 subjects 30-70 years of age with a history of at least 2 colds in the previous year will be recruited from the general population in jeollabuk-do, South Korea. The subjects will be instructed to take 9 capsules per day of either the Korean red ginseng extract or a placebo for a period of 12weeks. The primary outcome measure will be the number of Jackson-verified colds. Secondary outcome measures will be included symptom severity, total number of days of symptoms and duration of all colds. Cold symptoms will be scored by subjects.